Trending: Bristol Myers Squibb to Buy RayzeBio
26 Décembre 2023 - 4:28PM
Dow Jones News
0958 ET -- Bristol Myers Squibb is one of the most mentioned
companies in the U.S. across all news items in the last 12 hours,
according to Factiva data. The drugmaker has agreed to buy
radiopharmaceutical therapeutics company RayzeBio for $4.1 billion.
Dow Jones & Co. owns Factiva. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
December 26, 2023 10:13 ET (15:13 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
RayzeBio (NASDAQ:RYZB)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
RayzeBio (NASDAQ:RYZB)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
